Why statin therapy may increase the risk for posttransplantation squamous cell carcinoma.
We suggest that surveillance for squamous cell cancer might be particularly useful for transplant patients receiving statin therapy. We recommend that development of non melanoma skin cancer should be specified as a secondary endpoint in future large endpoint statin trials, and suggest that in transplant patients the adverse effects of statin drugs may outweigh benefits, especially in women and the elderly, a subset of population in which even individuals at high risk for cardiovascular disease have shown no trend to net benefit from statins.